APA (7th ed.) Citation

Halmos, B., Cobb, P., Johnson, M., Jain, L., Kim, S., Saraf, S., . . . Kurata, T. (2021). 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC). Annals of Oncology, 32, S1456. https://doi.org/10.1016/j.annonc.2021.10.187

Chicago Style (17th ed.) Citation

Halmos, B., P. Cobb, M.L Johnson, L. Jain, S.J Kim, S. Saraf, M. Lala, and T. Kurata. "168TiP KEYNOTE-A86: Phase III, Randomized, Open-label Study of First-line Subcutaneous (SC) Vs Intravenous (IV) Pembrolizumab with Platinum Doublet Chemotherapy in Metastatic Squamous or Nonsquamous Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology 32 (2021): S1456. https://doi.org/10.1016/j.annonc.2021.10.187.

MLA (9th ed.) Citation

Halmos, B., et al. "168TiP KEYNOTE-A86: Phase III, Randomized, Open-label Study of First-line Subcutaneous (SC) Vs Intravenous (IV) Pembrolizumab with Platinum Doublet Chemotherapy in Metastatic Squamous or Nonsquamous Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology, vol. 32, 2021, p. S1456, https://doi.org/10.1016/j.annonc.2021.10.187.